Vor Biopharma to Present at the Barclays Global Healthcare Conference
March 05, 2021 15:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
March 01, 2021 15:45 ET
|
Vor Biopharma
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
February 09, 2021 16:05 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...
Vor Biopharma Announces Pricing of Initial Public Offering
February 05, 2021 06:33 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...